Cantargia ABCHIX:CANTAS 37 PS Ratio is 3.27 as of Jul. 04, 2026, which is 7% above its 10-year median of 3.05. GuruFocus rates CHIX:CANTAS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 933 Biotechnology companies, Cantargia AB ranks better than 87.03% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cantargia AB's share price is kr4.174.
Cantargia AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.28. Hence, Cantargia AB's PS Ratio for today is 3.27.
Good Sign:
Cantargia AB stock PS Ratio (=1.71) is close to 1-year low of 1.66.
The historical rank and industry rank for Cantargia AB's PS Ratio or its related term are showing as below:
CHIX:CANTAs'
s PS Ratio Range Over the Past 10 Years
Min: 1.66 Med: 3.05 Max: 4.87
Current: 1.71
During the past 13 years, Cantargia AB's highest PS Ratio was 4.87. The lowest was 1.66. And the median was 3.05.
CHIX:CANTAs's PS Ratio is ranked better than 87.03% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs CHIX:CANTAs: 1.71
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Cantargia AB PS Ratio Related Terms
Cantargia AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Cantargia AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CANTAS vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Cantargia AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantargia AB PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cantargia AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cantargia AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cantargia AB's PS Ratio for today is calculated as
Cantargia AB's Share Price of today is kr4.174. Cantargia AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.28.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cantargia AB (CHIX:CANTAS) has a PS Ratio of 3.27 as of Jul. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cantargia AB and its competitors. This is near median its historical median of 3.05. Over the past decade, Cantargia AB's PS Ratio has ranged from 1.66 to 4.87. According to the industry distribution chart, Cantargia AB ranks #121 out of 933 companies in the Biotechnology industry, placing it in the top 13%.
Is Cantargia AB's PS Ratio too high?
Cantargia AB's current PS Ratio of 3.27 is near median its 10-year median of 3.05. Over the past 10 years, this metric has ranged from a low of 1.66 to a high of 4.87. The Biotechnology industry median PS Ratio is 9.64. Cantargia AB's value of 3.27 is 66.1% below this industry median. Based on the distribution chart, Cantargia AB ranks #121 out of 933 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cantargia AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cantargia AB ranks #121 out of 933 companies for PS Ratio. This places Cantargia AB in the top 13% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.64. Cantargia AB's value of 3.27 is 66.1% below this benchmark. Historically, Cantargia AB's own PS Ratio has ranged from 1.66 to 4.87 over the past decade. While the company's 10-year median is 3.05 vs. the industry median of 9.64, Cantargia AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cantargia AB's current PS Ratio of 3.27 is 66.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cantargia AB and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantargia AB's current PS Ratio is 3.27, which is near median its own 10-year median of 3.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current PS Ratio of 3.27. The current PS Ratio is 3.27, which is near median its 10-year median of 3.05 and 66.1% below the Biotechnology industry median of 9.64. Cantargia AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current PS Ratio is 3.27 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score
Get the complete analysis for CHIX:CANTAS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CANTAS has been successfully added to your 
